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  The aim of this study was to assess the efficacy of mavacoxib, a cox-2 inhibitor, to 
improve the peak vertical force (PVF) and vertical impulse (VI) of lame client-
owned dogs with severe coxofemoral osteoarthrosis (OA) by using a force platform. 
A group of ten canarian presa dogs with lameness and pain for a severe 
osteoarthrosis due to hip dysplasia were used for this study. Five additional sound 
dogs of the same breed were used as control groups. A single force platform used to 
register vertical forces was mounted in a 7 m runway. Mean (± SD) values for speed 
of dogs were 1.6±0.5 m/s. Data corresponding with 5 valid trials were recorded at 
walk at day 0, 7, 60 and 180 after starting treatment procedure. The dosing regimen 
consisted of a loading oral dose of 2 mg⁄ kg to be repeated after 14 days, thereafter 
the dosing interval was 1 month. OA dogs showed a significant improvement of 
PVF after two months of about 7% bm in the force exerted by diseased limbs and a 
significant VI improvement after two months of about 1.6% bm in the VI exerted by 
diseased limbs. This study clearly showed that dogs treated with mavacoxib 
increased PVF over time, as soon as seven days after medical therapy, 
demonstrating a high potential for clinical use in the treatment of lameness 
associated with OA of hip joint. 
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INTRODUCTION 
 
Objective evaluation of gradual recovery of lameness 
during or after treatment is a discussed topic
 (Mölsä et al., 
2010). Veterinary clinicians assess pain severity in their 
patients based on vocalization, activity level, degree of 
lameness, and reaction to manipulation; however, all these 
methods are subjective and may be influenced by external 
factors. Moreover, pain scoring systems also do not provide 
a fully objective evaluation
 (Horstam et al., 2004).  
Biomechanical measurement of ground reaction 
forces (GRF) in dogs is a well-established method used to 
describe both normal canine gait and the type/severity of 
lameness. Force platform gait analysis is an objective, 
quantitative, non-invasive and reliable method to 
characterize the ground reaction forces during locomotion 
both in humans and dogs
  (Anderson and Mann, 1994; 
Ragetly  et al., 2012). Force platform gait analysis has 
been consistently used in dogs after cranial cruciate 
ligament surgery (Jevens et al., 1993), total hip 
replacement (Budsberg et al., 1996; Dueland et al., 2001), 
triple pelvic osteotomy (Tano et al., 1998) and dorsal 
laminectomy (Van Klaveren et al., 2005; Suwankong et 
al., 2007), as well as to verify the efficacy of different 
therapeutical strategies for the treatment of osteoarthrosis 
(OA) in dogs (Hielm-Björkman et al., 2012; Eskelinen et 
al., 2012) 
Some authors demonstrated that about 20% of all 
dogs are presented at some time during their life with 
clinical signs of OA at veterinary practices. Aim of OA 
treatment in dogs is to neutralize the irreversible structural 
changes and it often involves medical therapy, including 
administration of non-steroidal anti-inflammatory drugs 
(NSAIDs), which have been shown to produce clinical 
benefits
  (Sanderson  et al., 2009
;  Moreau  et al., 2010). 
Therefore, it is assumed that control of pain and 
inflammation will increase the functionality of the OA 
affected joints (Pelletier et al., 2000). 
Mavacoxib (Trocoxil™, Pfizer, MY, USA) is a 
NSAID cyclooxygenase-2 (COX-2) inhibitor, structurally 
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related to celecoxib (Penning et al., 1997). The 
metabolically labile aromatic methyl substituent of 
celecoxib has been replaced in mavacoxib with a 
metabolically stable fluoro-substituent
  (Paulson  et al, 
2000). This change resulted in a compound with low 
clearance and a prolonged t½
 (Cox et al., 2010). These 
pharmacokinetic characteristics make Mavacoxib unique 
among other NSAIDs (e.g. carprofen, celecoxib, 
deracoxib), that have clearance values at analgesic or 
therapeutic osteoarthritic doses in laboratory dogs more 
than six times greater than mavacoxib (Paulson et al., 
2001). 
In previous studies, the efficacy of NSAIDS was 
verified using a single force plate mounted in a walkway, 
and the dogs were walked or trotted over the plate 
(Bockstahler  et al., 2007). The aim of this study is to 
assess the efficacy of mavacoxib to improve the weight-
bearing capacity of lame client-owned dogs with OA 
secondary to hip dysplasia, by using a force platform to 
measure PVF and VI. 
 
MATERIALS AND METHODS 
 
Animals:  10 adult canarian presa dogs (5 males, 5 
females) with lameness and pain attributed to 
osteoarthrosis by hip dysplasia were eligible for inclusion 
in the study. None of the dogs was forced to develop 
physical activity. A x-ray examination was required to 
confirm the presence of osteoarthrosis as evidenced by 
subchondral bone sclerosis, bone remodelling, 
osteophytes or enthesophytes in the affected joint (degrees 
D and E of hip dysplasia for the International Cinologic 
Federation).  
Additional radiographs of knee and elbow joints, 
physical and orthopedic examinations were performed to 
ensure that hip osteoarthrosis was the main reason for the 
observed clinical signs and general health was otherwise 
normal. Moreover, dogs included in this study needed to 
be affected by chronic OA and not have received, for at 
least 2 months, any kind of medications (e.g. non-steroidal 
anti-inflammatory drugs, analgesics), nutraceuticals (e.g. 
glucosamine or chondroitin, vitamin E, omega 3 fish oil), 
or adjunctive therapies (e.g. acupuncture). The control 
group consisted of five sound and healthy dogs of the 
same breed. 
The dosing regimen for OA group consisted of a 
loading dose of 2 mg⁄ kg bw to be repeated after 14 days, 
thereafter the dosing interval was 1 month.  
 
Measurements: A single, dynamometric and permanently 
mounted force platform (Pasco®, California, USA) was 
used to acquire PVF and VI. The device platform was 
mounted in the center of, and level with, a 7 m runway 
covered by a rubber carpet. In order to avoid 
interferences, the carpet covering the force platform was 
independent of the surrounding.  All dogs were always 
guided at walk over the force plate by the same handler. 
Velocity was measured by use of a motion sensor 
(Pasco®, California, USA) positioned 1m apart.  
Five valid trials at a sampling frequency of 250 Hz 
were obtained of each animal. A trial was considered 
valid when the limb fully contacted the force platform, 
and with the dog walking next to the handler without 
pulling on the leash. The trial was discarded if the dog 
was distracted during the measurement, or if the limb 
struck the edge of the force plate or any portion of the 
contra-lateral paw hit the force plate. One member of the 
research team evaluated the trial to confirm which limb 
touched the center of the force platform. 
The platform was interfaced with a dedicated 
computer using datastudio (Pasco®, California, USA), a 
software specially designed for the acquisition, numerical 
conversion and storage of data. Acquisition of data was 
performed before starting treatment (D0) and at day (D): 
D7, D60 and D180.  The obtained PVF (N) and VI (N.s) 
were normalized relative to body weight (% BW) to 
characterize the possible improvement of the lameness 
during the treatment with mavacoxib (Bertram et al., 
2000; Horstam et al., 2004). Although each dog had a 
bilateral lameness, only the more severely affected hind 
limb (lesser PVF) was chosen for study to limit a possible 
bias caused by inconsistent weight redistribution to the 
less affected contra-lateral hind limb. 
 
Statistical analysis: Data were analyzed by a different 
(blind) researcher to whose performed acquisition of data. 
For the analysis of these data a linear mixed effects model 
was considered: the experimental factor (time) was a fixed 
effects factor, while the blocking factor (dog) was a 
random effects factor. Parameters in this model were 
estimated by using the package nlme in the R statistical 
software (Sun and Li., 2011). Signification of the 
differences in supporting force or vertical impulse 
between periods of observation was tested by means of 
the analysis of variance. Following this analysis, post-hoc 
comparisons between fixed effects had been performed by 
using Tukey procedure. For assessing the validity of the 
model, Shapiro-Wilk test was applied for testing 
normality of the residuals, and Levene test for testing 
homoscedasticity. The significance level was set at 
P<0.05 in all tests. 
 
RESULTS 
 
The body weight of enrolled dogs ranged from 39 to 
54 kg (48.3±4.6 kg) and was 2-8 years of age (3.7±1.5 
years). Mean values for velocity of dogs were 1.6±0.5 
m/s. No significant difference existed between dogs in 
average walking velocity (P=0.055).  PVF and VI mean 
values are shown (Table 1).  
 
Table 1: Mean and standard deviation of PVF and VI (in % of the dog 
weight) applied on the diseased leg. Data are shown for each day of 
observation. PVF L: peak vertical force in the lame group. PVF S: peak 
vertical force in the control group. VI L: vertical impulse in the lame 
group. VI S:vertical impulse in the control group 
PVF L  Day  Mean  sd  VI L  day  Mean  sd 
 0  37.25  5.93    0  13.32  0.73 
 7  40.20  4.84    7  13.70  0.32 
 60  43.32  1.34    60  14.78  0.64 
 180  43.93  3.02    180  15.30  0.85 
PVF S  0  47.40  3.39  VI S  0  13.75  0.21 
 
Analysis of variance showed that the differences in 
PVF between periods of observation were significant 
(P<0.0001, F=60.975 with 4 and 27 degrees of freedom). 
Particularly, we emphasized the increasing in supporting 
force after six months of treatment: the difference after Pak Vet J, 2013, 33(2): 229-233. 
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two months (about almost a 7% of increase) was already 
significant (P=0.0003). From the second month onwards 
there was no substantial improvement in supporting force 
(P=0.98). Finally we compared the mean supporting force 
after six months of treatment with that of the healthy 
group of dogs: the estimation of percentage (%) of 
supporting force in dogs after 6 months of treatment was 
of 43.9%. whilst for healthy dogs the mean percent of 
supporting force was estimated as 47.4%, but this 
difference didn’t result significant (P=0.4170) (Fig. 1).  
The validity of the model fit was assessed by testing 
normality and homoscedasticity of the residuals. Both 
assumptions could be accepted: Shapiro-Wilk test for 
normality gave  P=0.1218 and Levene test for 
homoscedasticity gave P=0.5227.  
Analysis of VI showed significant changes after two 
months (P≤0.001). From the second month there was no 
substantial improvement in VI (P=0.32). Moreover, 
comparing the VI after six months with that of the healthy 
group, in diseased dogs it was of 15.3%, while for healthy 
group was 13.7%. This difference was again non-
significant (P=0.3289) (Fig. 2). The validity of the model 
fit was assessed by testing normality and 
homoscedasticity of the residuals. Both assumptions could 
be accepted because Shapiro-Wilk test for normality had a 
P=0.1505 and Levene test for homoscedasticity had a 
P=0.4285. 
 
 
 
Fig. 1: Evolution of PVF in lame group dogs after treatment during the 
six months follow up period. 
 
 
 
Fig. 2:  Evolution of VI in lame group dogs after treatment during the 
six months follow up period. 
DISCUSSION 
 
The primary intent of using force platform analysis in 
our study was to investigate this technique as an objective 
method to evaluate the NSAID efficacy in the locomotor 
system. In this trial, efficacy of mavacoxib in lame 
osteoarthritic dogs was investigated observing the PVF 
and VI; because other scoring measurement systems to 
evaluate the severity of pain in the dog should be partially 
influenced by a variety of human and/or animal behaviors 
and physiologic conditions as tested by other authors
 
(Horstam et al., 2004). Horstam et al., (2004) suggested 
that platform analysis determined how much load patients 
place on the limb and it avoided observer and inter-
observer variations that were encountered with pain 
scoring systems. 
The relationship between radiographic signs of OA 
and limb function has been described to be poor in 
previous reports
 (Roy et al., 1992). In a recent study with 
force platform analysis
  (Gordon  et al, 2003), no 
correlation was found with the radiographic OA score of 
osteoarthritic dogs, and other authors
 (Bockstahler et al., 
2007) advise against the use of this technique to assess 
osteoarthrosis. However, in our study we performed a X-
ray examination in order to select only dogs with the most 
severe degrees of hip dysplasia (D - E), which ensured the 
presence of OA. 
The objective improvement in both parameters (PVF 
and VI) of the support phase, after treatment, indicated 
that dogs were able to execute a walking gait more 
comfortably, with less reticence and more weight support 
(Fig. 3). This effect was observed after one week of 
treatment, more rapidly than in a similar study 
administrating carprofen® and meloxicam®, where 
objective improvement was detectable after 60 days of 
treatment increasing PVF GRF in a median value of 2.4% 
bw
  (Moreau  et al., 2003). In our study, diseased dogs 
improved in almost 8% bw. Although evolution of 
lameness was expressed as a mean of all dogs, the 
behavior of results could be very different depending on 
the degree of lameness: dogs with worse weight bearing 
developed a faster and greater improvement during the 
treatment period. 
 
 
 
Fig. 3: Graph showing loading range at day 0 (dotted) and day 180 
(solid). Note that not only PVF ant support time increased, even the 
shape clearly changed to a more typical two-peaks curve. 
 
In our study, force platform analysis resulted sensible 
to detect changes in the forces applied by lame limbs 
through a treatment period, as reported by other authors in 
previous experiments (Budsberg et al., 1996; Tano et al., 
1998; Moreau et al., 2003; Holstam et al., 2004). Hence, 
this method allowed a full documentation of the kinetic Pak Vet J, 2013, 33(2): 229-233. 
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benefits provided by pharmaceutical and physical 
therapies for orthopedic conditions observing forces that 
generate movement. 
Patient velocity had a significant effect on force 
platform values and it must be limited to a narrow range 
when data were obtained (Paulson et al., 2001); for this 
reason, the enrolment of dogs with the same conformation 
(same breed) ensured a narrow range of velocities that 
they could develop. Force platforms inserted in treadmills 
allow avoiding factors that could produce variability in 
results, such as speed; however, studies with this device 
were limited by the size of the dog, since in larger 
animals, stride length exceed the limits of the platform 
and parameters as VI could not be measured (Bockstahler 
et al., 2007).  
Focusing on gait, some authors proposed trot as a 
better gait to perform gait analysis because low grade 
pelvic limb lameness was more easily detected at trot than 
during walking
 (Voss et al., 2007; Colborne, 2008). In our 
case, lameness of the OA dogs group was so evident by 
direct observation, even at walk. 
Body weight and conformational variables (e.g. 
femoral length) were also main factors influencing force 
platform values. Consequently, these variables needed a 
statistical normalization of peak forces and other 
parameters with a linear scaling, in order to be used as a 
standard to minimize the effect of body weight on ground 
reaction data and to allow comparison of animals with 
differing body weights or anatomic conformation 
(Bertram  et al., 2000). In our study, statistical 
normalization was not used because the efficacy of the 
treatment on dogs with OA was assessed comparing the 
gait improvement of each dog with its D0 value, gaining 
force exerted by the lame limb, expressed in % bw. 
Bockstahler et al. (2007) demonstrated the negative 
impact of body weight gain on GRF values, and 
conversely, the improvement in weight support when 
body weight decreased, considering that joint loading is a 
painful action when OA is present. In accordance with 
their observation, we paid special attention to explaining 
to owners that they should not change feeding of their 
dogs during the study period. However, if the weight was 
changed, because of the resultant forces were expressed in 
% bw, results could not be significantly modified. 
Asymmetry should be a factor to take into account, 
since significant differences were found in peak vertical 
forces between right and left thoracic limbs. According to 
the results found by Molsa et al. (2010) in Labrador 
Retrievers, dogs put significantly more weight on the right 
thoracic limb than on the left one. However, the author 
did not explain this asymmetry. This factor could interfere 
with the interpretation of results comparing limbs of both 
sides; however, in our study, we performed measurements 
in individual limbs, compared with them during the study 
period. 
Literature reported that conventional NSAIDs, by 
inhibiting COX-1, can disturb gastric tissue homeostasis, 
leading to serious gastroduodenal damage (Reimer et al., 
1999). Selective COX-2 inhibitors minimize this effect, 
although some authors reported that a therapy 
administered to dogs for eight weeks produced and 
increased lesions in the gastroduodenal mucosa
 (Moreau 
et al., 2005). In our study, NSAID treatment was well 
tolerated, as demonstrated by the dogs’ owners’ failure to 
notice any clinically relevant disturbances or adverse 
effects. Moreover, the prolonged mavacoxib t½ associated 
with constant and progressive improvement of lameness 
supported our protocol that required doses separated by 2–
4 weeks, rather than a once-daily NSAID administration 
(Cox et al., 2010). 
 
Conclusion: This study clearly showed that dogs treated 
with mavacoxib increased PVF over time, as soon as 
seven days after medical therapy, demonstrating a high 
potential for clinical use in the treatment of lameness 
associated with OA of hip joint. 
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